{"analyses":[{"ciPctValue":"95","groupDescription":"Adjustments for multiplicity was done using a closed test procedure which tests for differences between all three treatment groups at the 5% alpha level first. Only in case of a significant result, the pair-wise comparison between the control arm and each of the bevacizumab arm will be tested, again at the 5% alpha level.","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2024","statisticalMethod":"Closed test procedure","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"comment":"Median time to event and 95% confidence intervals could not be estimated due to the low number of events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median time to event and 95% confidence intervals could not be estimated due to the low number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median time to event and 95% confidence intervals could not be estimated due to the low number of events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"955"},{"groupId":"OG001","value":"960"},{"groupId":"OG002","value":"952"}],"units":"Participants"}],"description":"Disease-free survival (DFS) was defined as the time from the date of randomization to the time of a recurrence, a new occurrence of colorectal cancer or death due to any cause, whichever occurred first. Patients without an event were censored at the last date the patient was known to be disease-free. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Patients with no tumor assessments after baseline but still alive at the time of the clinical cut-off were censored at day 1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Weeks 1-24: Oxaliplatin was administered as an 85 mg/m\\^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m\\^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m\\^2 bolus injection, and then as a 600 mg/m\\^2 continuous infusion over 22 hours. Leucovorin 200 mg/m\\^2 (alone), followed by 5-FU 400 mg/m\\^2 bolus injection, and 5-FU 600 mg/m\\^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).\n\nWeeks 25-48: Observation only.","id":"OG000","title":"FOLFOX4"},{"description":"Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m\\^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m\\^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m\\^2 bolus injection, and then as a 600 mg/m\\^2 continuous infusion over 22 hours. Leucovorin 200 mg/m\\^2 (alone), followed by 5-FU 400 mg/m\\^2 bolus injection, and 5-FU 600 mg/m\\^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).\n\nWeeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).","id":"OG001","title":"FOLFOX4 + Bv"},{"description":"Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m\\^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m\\^2 twice daily (equivalent to a total daily dose of 2000 mg/m\\^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).\n\nWeeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).","id":"OG002","title":"XELOX+Bv"}],"paramType":"MEDIAN","populationDescription":"The primary population for efficacy analyses was the intent to treat population (ITT; all randomized patients) with stage III disease.","reportingStatus":"POSTED","timeFrame":"From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).","title":"Disease-free Survival in Stage III Cancer Patients - Time to Event","type":"PRIMARY","unitOfMeasure":"months"}